Summit Therapeutics (SMMT) Proxy filing summary

Executive summary

• Special meeting scheduled virtually for November 4, 2026; record date October 1, 2026, with 799,726,418 common shares outstanding and entitled to vote.

• Stockholders will vote on raising authorized common shares by 1 billion, from 1 billion to 2 billion; the board unanimously recommends approval.

Voting matters and shareholder proposals

• Proposal 1 requires approval by a majority of votes cast; abstentions and broker non-votes have no effect, and brokers may vote uninstructed shares because the proposal is routine.

• Votes by Internet or telephone are due by 11:59 p.m. ET November 3, 2026; stockholders may also vote during the virtual meeting.

• Rule 14a-8 proposals for the 2027 annual meeting must be received by December 18, 2026; advance-notice and universal-proxy deadlines also apply to nominations and other business.

Board of directors and corporate governance

• The board unanimously adopted the charter amendment as advisable and in stockholders’ best interests, and recommends a FOR vote.